Cryptococcal meningitis …

Joseph R Berger MD

Infectious Disorders

Updated 01.04.2024
Released 11.29.1994
Expires For CME 01.04.2027

Cryptococcal meningitis

Author: Joseph R Berger MD

See Contributor Disclosures

Editor: John E Greenlee MD

Cryptococcal meningitis

In This Article

Quick Link

Introduction

Overview

Cryptococcal meningitis is the most common form of meningitis observed in AIDS, affecting 1% to 10% of patients; conversely, HIV is the greatest risk factor for cryptococcal infection. Other immunosuppressive conditions also predispose to its development, such as corticosteroid administration; however, it may also be seen in immunologically normal persons. Cryptococcal meningitis may be difficult to diagnose as its clinical features are often subtle. Headache is the most common symptom, but it is not universally present, and papilledema occurs in less than one third of persons. On occasion, cryptococcal infection of the CNS presents as mass lesion in the brain (cyst, granuloma, or abscess) or as encephalitis. The toxicity of the antifungal drugs, particularly amphotericin, may render treatment difficult. In the AIDS population, long-term prophylaxis may be required.

Key points

	• Cryptococcal meningitis is the most common fungal meningitis and needs to be considered in the differential diagnosis of anyone with unexplained meningitis.
	• Although meningitis is the most common neurologic manifestation of cryptococcal infection, CNS mass lesions and vascular insults may also occur.
	• Cranial imaging studies either with CT scan or MRI in patients with cryptococcal meningitis may be unrevealing.
	• CSF cryptococcal antigen studies are typically, but not invariably, positive in cryptococcal meningitis.

Historical note and terminology

Human cryptococcal infection was first described during the last decade of the 19th century. Busse, a pathologist, and Buschke, a surgeon, separately reported the isolation of yeast from the tibia of a young woman (18; 17). In 1905 the yeast was identified as a CNS pathogen when von Hansemann described the first case of cryptococcal meningitis (69).

Several different terms have been applied to the fungus currently referred to as Cryptococcus neoformans. Familiarity with these terms is helpful in reading the older literature. Busse employed the term “Saccharomyces hominis” because of the sarcoma-like appearance of the patient’s lesions (18). The fungus was transferred to the genus Cryptococcus by Vuillemin because of the absence of ascospores (175). Subsequently, the term “neoformans” was included to indicate “cancer or tumor-causing” in light of an association between the isolation of the organism and cancers. In 1916 Stoddard and Cutler distinguished between cryptococcus, blastomyces, and other mycoses (161). They named Cryptococcus “Torula histolytica” because of the mistaken belief that the cysts observed in tissues were the consequence of digestive actions of the organism. However, this term is no longer in use.

Clinical manifestations

Presentation and course

	• Cryptococcal meningitis typically evolves in a subacute fashion.
	• Headache and fever are the most common manifestations but are not invariable.
	• Altered mental status and transient visual loss may occur.
	• Features suggesting meningeal irritation are observed in only a minority of patients.

Cryptococcus may present with several different clinical patterns. Often, the infection is subclinical. It appears that exposure to C neoformans and subsequent sensitization without the appearance of clinical illness is not uncommon. Organs that may be sites of clinically apparent infection most commonly include the lung, CNS, skin, bone, and prostate, but others may be affected as well. Simultaneous dissemination to multiple sites may be observed. For instance, AIDS patients with overwhelming immunosuppression and cryptococcal meningitis have been described with skin lesions due to C neoformans (103). Some of these lesions may mimic molluscum contagiosum (103).

Molluscum-like lesions due to disseminated cryptococcus

(Contributed by Dr. Joseph Berger.)

Cryptococcal meningitis is estimated to account for 40% to 86% of the estimated cases of symptomatic cryptococcal infection. The frequency of disseminated infection in the setting of cryptococcal meningitis is highlighted by the occurrence of abnormal chest radiograph opacities compatible with cryptococcal lung infections in 25% of patients with cryptococcal meningitis (70) and by the relatively high frequency with which the organism can be isolated from blood. The clinical presentation of cryptococcal meningitis appears similar in both immunocompetent and immunocompromised persons (86).

Cryptococcal meningitis generally progresses slowly; it is seldom explosive in onset. Patients with cryptococcal meningitis most commonly complain of headache, usually frontal or temporal in location. Headache is not invariable, and the combination of headache and fever occur together in only 67% to 82% of some large series of AIDS patients with cryptococcal meningitis. However, a study of nearly 300 HIV-infected persons with cryptococcal meningitis found that headache occurred in 99% (44). Neck stiffness was observed in approximately 70%. Mental status changes and alterations of level of consciousness are frequent. Nausea or emesis is present in about 45% of cases, whereas photophobia and features of meningeal irritation are remarkably uncommon for meningitis in general, occurring in less than a third of cases. Seizures occur in 4% to 18%, and cognitive impairment or alterations in sensorium occur in 17% to 24%. Episodes of transient loss of consciousness may be the heralding symptom (181). Cranial neuropathies are seen in up to 15%. Focal neurologic deficits occur in 5% to 15% of cases. Dizziness, cerebellar ataxia, and syncope have also been noted as presenting features (87; 191; 34; 35; 138). Mesencephalic abscesses complicating cryptococcal meningitis have resulted in a clinical presentation mimicking Parkinson disease (14). Myelopathy with an acute flaccid paraplegia and polyneuroradiculopathy may also complicate cryptococcal meningitis on rare occasion (39).

Visual symptoms may occur in up to 21% of cases and neuro-ophthalmic findings in up to 33% (72; 138). Impaired visual acuity may be the presenting manifestation in some patients (117). Visual symptoms may include transient, abrupt, or progressive loss of visual acuity in one or both eyes due to increased intracranial pressure (49), necrotizing optic neuropathy from cryptococcal infiltration (116; 36), or compression of the optic nerve with vascular compromise (98). Diplopia may be intermittent or persistent and may be associated with cranial neuropathies, skew deviation, internuclear ophthalmoplegia, and nystagmus (60; 83; 84; 58; 141). Papilledema occurs in 1.5% to 12% of cases (72; 138). Visual field deficits may be homonymous, bitemporal, or altitudinal (60; 66; 63). Visual symptoms may be the first indication of recurrent cryptococcal meningitis in AIDS patients on maintenance antibiotic therapy (66). Involvement of vestibulocochlear nerve may result in vertigo and hearing loss (132).

Psychiatric symptoms may also be presenting features of cryptococcal meningitis. Psychosis (35) and behavioral changes (139) have been noted. Mania as an isolated presenting symptom has been described in two patients, one of whom responded to successful therapy of his meningitis with complete resolution of the manic syndrome (78). In some cases, no signs of neurologic disease are present, and diagnosis arises during the evaluation of systemic symptoms (191; 138).

Analogous to the immune reconstitution inflammatory syndrome (IRIS) that occurs following the administration of highly active antiretroviral therapy in HIV-infected patients with tuberculosis and progressive multifocal leukoencephalopathy, a similar disorder may be observed in cryptococcal infection (76). IRIS typically occurs within three months of the initiation of highly active antiretroviral therapy (16). IRIS takes two forms, “paradoxical” cryptococcal IRIS is a worsening of symptoms that occurs in individuals with established disease, and “unmasking” cryptococcal IRIS is the unexpected development of de novo cryptococcal meningitis following the initiation of antiretroviral therapy (115). Distinguishing IRIS from recurrent disease may be difficult (115). In a review of the disorder, 13% of 101 AIDS patients with cryptococcal meningitis receiving HAART developed IRIS (163); an increased baseline serum cryptococcal antigen was a risk factor. In another review, the median CD4 count at the time of diagnosis of cryptococcal meningitis was 25 cell/ml and at the time of IRIS 197 cells/ml (153). The underlying illness, eg, cryptococcal meningitis, may be inapparent until brought to light by the restoration of an effective immune response (16). The development of increased intracranial pressure in HIV-infected patients being treated for cryptococcal meningitis may be the consequence of IRIS (76; 184). Death ensues in up to one third of all patients with cryptococcal meningitis IRIS (149). A disorder characterized by clinical worsening following the initiation of treatment in immunologically young individuals has also been reported and referred to as postinfectious inflammatory response syndrome (PIIRS) (157). In one study, it was observed in 29% of immunocompetent individuals less than 50 years of age with cryptococcal meningitis (157).

Prognosis and complications

• A worse prognosis is associated with extremes of age, underlying disease (particularly HIV infection), extracerebral cryptococcosis, and high CSF pressure among other factors.

Factors associated with relapse are difficult to distinguish from those associated with poor survival. In general, the relapse rate and prognosis with cryptococcal meningitis appears to be variable. Survival has been reported in the range of days to more than 20 years in untreated cases. Among the factors that have been associated with relapse of cryptococcal meningitis following treatment are immunosuppression, neurologic manifestations at presentation, CSF leukocyte counts less than 20 cells/cu mm, CSF antigen titers greater than 1:32, positive CSF India ink studies following four weeks of treatment, and CSF antigen titers that exceed 1:8 after four weeks of treatment (166). These factors should be considered general rules as considerable disparity exists between the studies exploring prognosis in cryptococcal meningitis. Often confounding factors were not addressed. In a study in which potential confounds were examined, only the initial level of consciousness and CSF antigen titer were strongly associated with therapeutic failure (100).

Factors associated with a poor prognosis vary from study to study. An overall poor prognosis in cryptococcal meningitis has been associated with the following factors: young age (30); advanced age (170); abrupt onset (30); seizures (185); coma (185; 81); prolonged course over six weeks (30); extracerebral cryptococcosis (30); cryptococcemia (04; 146; 81); underlying illnesses (30), including HIV infection (170); corticosteroid administration (30); Cushing syndrome (48; 88); long-term antibiotics (30); high CSF pressure (30); and low CSF cells count (often neutrophilic leukocytes) (30). A study of mortality in cryptococcal meningitis unassociated with AIDS found lymphoma, semi-coma, leukocytosis, and initial high titers of cryptococcal antigen in cerebrospinal fluid (especially greater than or equal to 1:512) to be the best correlates and, on multivariate analysis, determined that lymphoma and initial high cryptococcal antigen titers were independent predictors of mortality (150). In HIV infection, significant prognostic factors include low CSF glucose; CSF with less than 20 cells/cu mm (139); high CSF lactate; high CSF cryptococcal antigen titer (greater than or equal to 1:1024) (191; 139); positive cultures of extrameningeal specimens (34); initial level of consciousness; the presence of seizure, hydrocephalus, and central nervous system vasculitis (100); neurologic impairment on initiation of therapy (35; 139); abnormal CT scan (35); and hyponatremia. A study of 501 HIV-infected patients with cryptococcal meningitis from four resource-poor countries demonstrated that CSF fungal burden, altered mental status, and rate of clearing of the infection were good predictors of acute mortality (73). In an HIV-infected cohort, measurement of CSF cytokines, chemokines, and macrophage activation markers demonstrated that interleukin (IL)-6 and interferon-gamma were most predictive of prognosis, although others, such as, IL4, IL-10, and IL-17, also contributed modestly (74). Three-year mortality in cryptococcal meningitis in one study correlated, after multivariate adjustment, with severe hyperglycemia (≥ 200 mg/dL) (170).

Clinical vignette

A 52-year-old woman presented to the emergency department with altered mental status. She had been diagnosed with AIDS nine months earlier when she presented with oral thrush, weight loss, and wasting. At that time her CD4 count was 4 cells/cu mm. She was started on combined antiretroviral therapy but stopped it three months before presentation. On examination, she was afebrile with a supple neck. She was unable to follow simple commands or answer questions. She withdrew all limbs to pain and exhibited normal limb strength and tone. Muscle stretch reflexes were symmetric and 1+ and bilateral Babinskis were noted. Laboratory studies showed a slight leukocytosis at 12,100 cells/cu mm with normal differential. Serum sodium was 124 mEq/L. Drug screen was negative, and she failed to respond to D50 or naloxone. A CT scan was negative, but cranial MRI revealed hyperintense signal abnormalities on T2-weighted image and FLAIR in the midbrain, thalamus, and left internal capsule.

Cryptococcal meningitis (cranial MRI)

(A) Cranial MRI with FLAIR imaging shows hyperintense signal abnormalities in the thalami and left internal capsule. (B) T1-weighted imaging with contrast shows enhancement in front of the brainstem (arrow). (Contributed by Dr. Jo...

Leptomeningeal enhancement that predominated around the brainstem was observed. Diffusion-weighted imaging and apparent diffusion coefficient mapping in these regions was consistent with acute infarction.

Cryptococcal meningitis (diffusion-weighted imaging and apparent diffusion coefficient mapping)

(A) Diffusion-weighted imaging shows hyperintense signals in the thalami and left internal capsule. (B) Apparent diffusion coefficient mapping shows hypointense signals in these same areas. (Contributed by Dr. Joseph Berger.)

CSF examination showed 58 WBCs/cu mm (79% lymphocytes, 4% monocytes, and 17% polymorphonuclear cells), CSF/serum glucose of 19/82 mg/dL, protein 98 mg/dL, negative cultures, strongly positive India ink, and positive Cryptococcal antigen. This patient illustrates the potential for basilar meningitis, in particular cryptococcal meningitis and tuberculosis, to be associated with cerebral infarction. In a study of stroke and TIAs in AIDS, 40% of infarcts and 8% of TIAs were associated with cryptococcal meningitis (57).

Biological basis

Etiology and pathogenesis

	• Two varieties of cryptococcus account for most human infections: C neoformans var neoformans and C neoformans var gattii.
	• C neoformans var neoformans causes most human infections.
	• C neoformans var gattii is seen more often in immunocompetent persons.

Cryptococcus neoformans, an encapsulated yeast, is a common soil fungus found throughout the world. Areas contaminated by pigeon droppings are particularly likely to contain this organism. It is often the predominant organism in desiccated alkaline environments with high nitrogen and high salt contents. It cannot compete successfully when soil mixing and irrigation foster the growth of other fungi and amoeba. C neoformans can remain viable after 2 or more years in moist or desiccated pigeon excreta. Antigenic variations in the polysaccharide capsule are used to define four serotypes, of which A and D most commonly cause human infections (09). Two varieties are distinguished: C neoformans var neoformans (serotypes A and D) and C neoformans var gattii (serotypes B and D). Both are members of the phylum Basidiomycota and are readily distinguished from other pathogenic yeasts by the presence of a polysaccharide capsule, formation of melanin, and urease activity; all function as virulence determinants (89). C neoformans is typically observed in the immunosuppressed population, such as in AIDS, whereas C gattii is reported more often in immunocompetent patients (89). C gattii is typically limited to subtropical and tropical zones and accounts for less than 20% of cryptococcal cases (89). However, in a review of immunocompetent persons less than 50 years of age, 63% of the identified strains were C neoformans, and only 17% were due to C gattii (157). C neoformans need not infect a vertebrate to complete its life cycle. In the animal model of disease, strain differences with respect to total capsule volume and rate of accumulation are correlated with neurovirulence (126). The differences in pathogenicity of the various strains of Cryptococcus has been proposed to be the consequence of immunogenic proteins secreted by each strain (19).

Human infection is usually acquired by inhalation of spores. The initial pulmonary infection is generally asymptomatic, although a self-limited pneumonia resolving over several weeks to months in the absence of treatment may be seen. Containment of the infection to the lungs is the consequence of both cell-mediated and humoral immunity (54). Pulmonary cryptococcosis includes the constellation of fever, cough, pleuritic pain, malaise, and weight loss. Occasionally, the cough is productive of blood-tinged sputum. The disease often affects both lungs and examination reveals diminished breath sounds, dullness to percussion, and, on occasion, a friction rub. Pulmonary infection generally resolves in its entirety, although the infection may persist as a mediastinal mass (134). Chest radiographs show variable patterns depending on the severity of the disease, the duration of the infection, and the host response.

Typically, the spread of C neoformans is limited to the lung and lymph nodes, but hematogenous dissemination may result in the seeding of other organs. The latter is particularly likely in the setting of immunosuppression. Alternatively, the organism may become reactivated from the sites of initial infection years later. Factors influencing dissemination include the polysaccharide capsule and secreted enzymes including laccase, phospholipase B, and urease (54). Resistance to infection is primarily dependent on cell-mediated immunity, although clinical infection occurs in both apparently normal and immunocompromised individuals (50). Most cases of cryptococcal meningitis are observed in individuals with underlying impairment in cell-mediated immunity (145), chiefly, in the setting of AIDS, lymphoreticular malignancies, sarcoidosis, connective tissue diseases, bone marrow and organ transplantation, and corticosteroid therapy. Humoral responses are generated by cryptococcal infection and may play a role in control of infection. Anti-cryptococcal immunoglobulins may be detected in the CSF of patients with cryptococcal meningitis (128); however, the absence of cryptococcal infection in persons with congenital or acquired humoral abnormalities indicates that this is of limited importance (68).

To a large degree, the tissue involved determines the nature of the pathological response to cryptococcal infection. In general, two types of histologic pattern occur with cryptococcal infection: (1) gelatinous and (2) granulomatous (06). Both types may coexist in the same lesion. The gelatinous lesions are characterized by masses of organisms and mucoid degeneration of the affected tissue. Granulomatous lesions are characterized by the presence of histiocytes, giant cells, lymphocytes, and variable degrees of a fibroblastic response.

Mouse studies indicate that Cryptococcus neoformans crosses the blood brain barrier by transcellular migration across brain endothelial cells (25) and then proliferates in the subarachnoid space resulting in leptomeningeal opacification with a gelatinous appearance. In HIV-infected individuals, the inflammatory response may be sparse and discrete, resulting in focal collections of macrophages and formation of giant cells. Focal granulomas composed of macrophages, lymphocytes, giant cells, and fungi may be seen. In cryptococcal meningitis, an exudate typically predominates at the base of the brain. This leptomeningeal exudate is usually gray-yellow in color and may extend over the surface of the cerebral and cerebellar hemispheres, although it predominates in the basal meninges. Extension into the ventricles and perivascular space is observed, and hydrocephalus may develop. Inflammation is usually, but not invariably, minimal.

Cryptococcal meningitis histopathology showing leptomeningeal inflammation and yeasts

(Contributed by Dr. Joseph Berger.)

The organisms extend along Virchow-Robin spaces where clusters of fungi may distend the perivascular space into adjacent parenchyma. This pathological process may also affect the spinal cord and nerve roots giving rise to myeloradiculitis (110). Intracerebral abscesses and cryptococcomas may be found in some cases. Mucicarmine staining demonstrates the capsule of the organism (93; 174). Tubercles averaging 2 to 3 mm in diameter may occur along blood vessels. A collection of yeast that distorts without destroying the brain and exhibits little or no surrounding inflammation or gliosis is referred to as a “gelatinous pseudocyst” (62).

Cryptococcal yeast infiltrating brain parenchyma

(Contributed by Dr. Joseph Berger.)

Typically, these lesions have been present for a relatively short period of time. Localized granulomatous lesions are referred to as “cryptococcomas,” “torulomas,” or “cryptococcal granulomas” (147).

Cryptococcoma of brain (MRI)

(Contributed by Dr. Joseph Berger.)

Although these lesions are chiefly observed in the cerebral hemispheres, they have also been reported in the cerebellum (82) and spinal cord (148). Persons with these lesions generally exhibit focal neurologic findings and have had the infection for a period of weeks or months.

Another cause of focal neurologic findings in the setting of cryptococcal meningitis is cerebrovascular disease (144; 186; 168; 65; 80; 92), which occurs as a consequence of perivascular granulomatous infiltration or from vascular occlusion at the time of brain herniation. Multiple ischemic insults can be observed, although this is distinctly unusual (136). Persons with AIDS have a higher incidence of parenchymal brain lesions and involvement of extracranial sites, as well as concomitant opportunistic infection (most often Pneumocystis carinii pneumonia) in 15% to 35% (166).

Cryptococcus is cleared by neutrophils and macrophages in a process that is mediated by complement, interferon, and T lymphocyte-derived lymphokines. Animal experiments reveal a critical role of interferon-γ for control of cryptococcal CNS infection and suggest that anti-CD40 and IL-2 therapy can be protective (189). The large polysaccharide capsule appears to be a virulence factor, inhibiting phagocytosis and leukocyte migration and activating the alternative complement pathway. One of the capsule’s defense mechanisms is the ability to produce a toxic polysaccharide that kills the engulfing macrophage (159). Survival in mammalian hosts is encouraged by the stimulation of capsular production by the physiologic concentrations of CO2 and by the low ferric iron concentrations found in the lung. Toll-like receptor 2 (TLR2) expression in patients with cryptococcal meningitis appears to be lower than in healthy controls and may contribute to the impaired host defense that naturally protects against development of the infection (188).

Cryptococcus has a particular affinity for the CNS, perhaps due to the absence of complement and soluble anticryptococcal factors present in serum and a diminished inflammatory response to the agent in brain tissue. A receptor on CNS cells for a ligand on the yeast has been proposed (77; 106) but has yet to be identified. Specific phenotypes of C neoformans appear to have a predilection for invasion of the nervous system. These include melanin production, the ability to thrive at body temperature, and the presence of a polysaccharide capsule (90; 24). In vitro experiments reveal that C neoformans causes marked alterations in the cytoskeleton of human brain endothelial cells resulting in swelling of mitochondria and endoplasmic reticulum, membrane ruffling, and irregular nuclear morphology with a resultant disruption of the blood-brain barrier (29). Elaboration of urease is also believed to be important in the disruption of the blood-brain barrier (54).

Epidemiology

	• An increasing incidence of cryptococcal meningitis predated the AIDS pandemic.
	• HIV infection remains the greatest risk factor for cryptococcal meningitis.
	• Cryptococcal meningitis is associated with a number of immunosuppressive drugs including some used in the treatment of multiple sclerosis, particularly, fingolimod.
	• Cryptococcal meningitis is seen an increasing number of persons without an underlying immune deficiency.

In the decades preceding the AIDS epidemic, the reported incidence of cryptococcal infection saw a dramatic increase (59). This increase was seen with other mycotic infections as well and was attributed to increasing numbers of persons with immunosuppressive conditions, migration of susceptible persons into hyperendemic areas, and aging of the population (59). With the advent of the AIDS epidemic in the 1980s, the incidence of cryptococcal infection, in particular cryptococcal meningitis, increased even more (87; 56; 107). Between 5% and 15% of untreated patients with AIDS in certain areas of the world will develop C neoformans disease during the course of their illness (164; 42). However, following the introduction of highly active antiretroviral therapeutic regimens, the incidence of cryptococcal meningitis has declined significantly in the HIV-infected population in western countries (140). However, this has not been a universal experience. For instance, in China, cryptococcal meningitis is the most common opportunistic infection in AIDS and is a significant cause of mortality (178). Cryptococcal meningitis may herald AIDS and occur in individuals not otherwise suspected to be HIV infected (11; 64). An epidemiological study from inpatient databases of 18 states in the United States identified 30,840 hospitalizations coded for cryptococcal meningitis (131). Only 21.6% of these cases occurred in HIV-uninfected persons. However, the incidence rates of cryptococcal meningitis have declined significantly during the antiretroviral therapy era, with rates of 3.7, 1.8, and 0.3 per 1000 person-years at risk in 1995 to 1996, 1997 to 1999, and 2000 to 2014, respectively (169). Despite declining incidence rates with HIV infection, monitoring cryptococcal antigenemia in HIV-infected persons with CD4 lymphocyte counts less than 200 cells/μL and treating those that are positive with fluconazole is recommended though there remains uncertainty as to whether this approach has reduced mortality (176). The potential magnitude of the problem has been illustrated by a study from India, a high burden country, in which cryptococcal antigenemia was detected in 60.8% of antiretroviral naïve patients and 39.2% of ART failures with CD4 lymphocyte counts less than 100 cells/μL (01).

Not unexpectedly, cryptococcal meningitis also occurs with increased frequency in a variety of other immunosuppressive conditions. For instance, it is a significant cause of morbidity and mortality in organ transplant recipients. In a study from the University of Pittsburgh, a major organ transplant center, the incidence of cryptococcal meningitis among transplant recipients was 0.5% (28/5521) (182). The greatest risk for development was among heart transplant recipients at 2.1% (8/372); however, the greatest mortality with the disease was in liver transplant recipients (182). Sarcoidosis (137) and idiopathic CD4 lymphopenia (143) are other risk factors for cryptococcal meningitis. Cryptococcal meningitis has been reported in multiple sclerosis patients treated with natalizumab (172) as well as with fingolimod (123; 31). Diabetes mellitus and liver cirrhosis are also risk factors for the disease. In a review of 28 published studies of cryptococcal meningitis with diabetes, all-cause mortality was 38.3% and mortality with meningitis was 36.2% (114). The 90-day mortality rate for cryptococcal meningitis with liver cirrhosis was 20% in one study (190).

Individuals without any recognized immunological deficiency continue to account for a substantial proportion of CNS cryptococcosis. In a study, immunocompetent persons comprised 43.5% of all the cases (101). In comparison to the immunocompromised group, immunocompetent individuals had a higher incidence of cryptococcal meningitis, lower rates of fungemia, and lower mortality (101). Among immunocompetent individuals, immunogenetics may contribute to the risk of cryptococcal meningitis. A study from China found an association with the HLA loci DQB1*05:02 and susceptibility to cryptococcal meningitis (99).

Prevention

• The high risk of cryptococcal meningitis in AIDS patients with CD4 counts less than 100 warrants either prophylactic therapy or careful serial monitoring of serum cryptococcal antigen levels.

Prevention is only relevant in the AIDS population. Two forms of prevention are possible. As the risk of cryptococcal meningitis is considerable in HIV-infected persons with CD4 T lymphocyte counts below 100 cells/cu mm, primary prophylaxis is considered in this population. An alternative to primary prophylaxis is screening for serum cryptococcal antigen positivity in those with CD4 T cells below 100 cells/cu mm as it correlates with an increased risk of cryptococcal meningitis and mortality in this population (13). Relapse is common in the patient with AIDS who has already suffered from cryptococcal meningitis. Prevention in that population is regarded as secondary prophylaxis.

Primary prophylaxis. The safety and efficacy of triazole antibiotics has raised the possibility of primary prevention in susceptible immunosuppressed HIV-infected individuals. An open label trial showed a reduced rate of cryptococcal meningitis in patients with CD4 levels less than 68/mm³ given 100 mg/day fluconazole compared to controls from the previous two years seen in the same site (113). One review suggested that primary prophylaxis be considered for patients with CD4 counts less than 50/mm³ but noted that the impact of such therapy on survival or on the susceptibility of various fungi to current agents is uncertain (125). A Cochrane Database review supported either fluconazole or itraconazole to reduce the incidence of cryptococcal disease in adults with advanced HIV infection (23).

Prevention of relapse. Early series of AIDS patients with cryptococcal meningitis treated only with acute therapy were associated with relapse rates of 50% to 60% (87; 191; 35). Open label trials of fluconazole (162) and itraconazole (45; 49) and a retrospective series in which some patients were given amphotericin B or ketoconazole (34) suggested survival benefit for maintenance therapy. A large placebo-controlled trial documented a 19% persistence of positive CSF cultures following six weeks of primary therapy with amphotericin alone or in combination with flucytosine and a significant benefit for fluconazole 100 to 200 mg/day in preventing relapse in patients with sterile CSF (15). Subsequently, a study comparing fluconazole 200 mg/day to amphotericin B 1.0 mg/kg per week found the former agent to be more effective with less toxicity (130).

Despite maintenance therapy, recurrent cryptococcal meningitis occurs in 2% to 16% of AIDS patients (34; 35; 15; 130). Serum cryptococcal antigen is not a reliable marker for CNS infection (56; 15). CSF cryptococcal antigen titers decline with successful therapy, but subsequent rises with recurrence are apparently acute and not predicted by routine monitoring of CSF (15). Persistence of cryptococcus in the prostate despite sterilization of CSF has been shown (94). Molecular genetic studies have revealed clonal identity of serial isolates obtained from three AIDS patients with recurrent meningitis (155). Although prospective studies have yet to be done on the natural history of persistently positive cultures in patients with suppression of clinical disease, it seems likely that recurrence results from sequestered organisms in CSF or elsewhere.

Failures of primary or secondary prophylactic therapy might potentially be due to resistant fungi. A case in which resistance to fluconazole appeared to evolve during therapy has been reported (118), and another in which resistance of a Cryptococcus neoformans var gattii species to fluconazole was noted (119). In a small series, no change in sensitivity of serial isolates to either fluconazole or amphotericin was detected, but there was a wide variation in the dose sensitivity to fluconazole among different isolates (21). Higher doses of fluconazole to 800 mg/day have been reported to be effective salvage therapy in patients failing conventional therapy with either fluconazole or amphotericin (12), and response may be observed in those resistant to amphotericin B (130).

In the era of highly active antiretroviral therapy with which a significant return to normal immune function may be observed, the necessity of secondary prophylaxis remains an open question. One prospective study addressing that issue found no recurrence of cryptococcal meningitis during a median 48-month follow-up in a group of patients with CD4 cell counts greater than 100 cell/cu mm and an undetectable HIV RNA level that had been sustained over three months (173).

Differential diagnosis

As cryptococcal meningitis may present in manifold fashions and is a treatable condition, it must be in the differential diagnosis of many clinical presentations including headache, encephalopathy, stroke, and seizure. The telltale features of meningitis, such as fever and signs of meningeal irritation, may be absent or relatively inapparent. On rare occasion, a cerebral cryptococcoma may even masquerade as a glioma (171).

Generally, the differential diagnosis of cryptococcal meningitis includes a broad range of other disorders that cause meningitis accompanied by a predominantly mononuclear CSF pleocytosis. Among the disorders that need to be considered are certain viral meningitides, some forms of bacterial meningitis (eg, tuberculous meningitis and partially treated bacterial meningitis), other fungal meningitides, parasitic meningitis (eg, amebic meningitis and trichinosis), carcinomatous and lymphomatous meningitis, drug-induced and chemical meningitis, and meningitis accompanying connective tissue diseases (eg, systemic lupus erythematosus and rheumatoid arthritis).

Diagnostic workup

Radiology. CT imaging is insensitive to cryptococcal meningitis, revealing nonspecific atrophy or no abnormalities in most instances (129; 127; 167). On rare occasion, unusual manifestations may be observed, such as CT demonstration of large, ring-enhancing, intraparenchymal lesions with intralesional calcification (05).

Leptomeningeal cryptococcal granulomata in nonimmunocompromised patient (1)

Postcontrast T1-axial and coronal imaging shows multiple small ring-enhancing nodules at ambient and quadrigeminal cisterns. (Contributed by Dr. Gaurang V Shah.)
Leptomeningeal cryptococcal granulomata in nonimmunocompromised patient (2)

Post-contrast T1-axial and coronal imaging shows multiple small ring-enhancing nodules at ambient and quadrigeminal cisterns. (Contributed by Dr. Gaurang V Shah.)
Leptomeningeal cryptococcal granulomata in nonimmunocompromised patient (3)

On FLAIR axial imaging, the nodules are isointense to CSF, but the capsule wall exhibits mild high signal. (Contributed by Dr. Gaurang V Shah.)

MRI is more sensitive than CT. In a study of 62 HIV-seropositive patients with cryptococcal meningoencephalitis, baseline imaging was abnormal in 53% of CT scans but in 92% of MRIs (27). Despite its increased sensitivity, MRI may still substantially underestimate the lesion burden found on pathologic examination (105). In immunocompetent individuals, multiple cystic lesions in the basal ganglia with marked ring enhancement (in contradistinction to the typical absence of contrast enhancement in the immunosuppressed individual) has been described (142).

Contrast enhanced imaging with MRI may reveal meningeal enhancement but appears to do so less frequently than in non-HIV-infected patients with cryptococcal meningitis. In a study comparing cryptococcal meningitis in HIV and non-HIV populations, normal brain imaging was observed in 44% of the former versus 13% of the latter (97). Parenchymal cryptococcomas may appear as enhancing mass lesions within the parenchyma (191; 167; 03). On diffusion-weighted MR imaging, cryptococcomas show a hypointense central cavity, which on apparent diffusion coefficient maps is hyperintense; these features mimic necrotic brain tumors rather than pyogenic brain abscesses (71). Miliary nodular enhancing leptomeningeal lesions have been noted uncommonly (167). In the absence of pathological confirmation, it is difficult to exclude the possibility of concurrent opportunistic pathology accounting for enhancing mass lesions (105).

Nonenhancing foci (which may be numerous in the basal ganglia and midbrain, displaying signal intensities similar to CSF) represent dilated Virchow-Robin spaces. On pathologic examination these may be filled with clusters of cryptococci and mucinous secretions. These collections have been referred to as gelatinous pseudocysts by some authors (127; 167; 105; 03). Cerebral infarcts may also occur with cryptococcal meningitis. In a study, 13% of patients had infarcts on MRI, with most common site of involvement being the basal ganglia followed by the thalamus, frontal, temporal, and parieto-occipital regions (108).

Cerebrospinal fluid. Identification of cryptococcus in the CSF is the gold standard for establishing the diagnosis. In contrast to non-HIV-infected individuals with cryptococcal meningitis, CSF abnormalities may be subtle in AIDS patients. The opening pressure is elevated in about two thirds and may exceed 500 mm of water. Animal studies suggest that C neoformans strain differences, such as the expression of glucorunoxylomannan, influences the degree of inflammation and the elevation of intracranial pressure (61). The CSF is typically clear, although on occasion, may be cloudy. Pleocytosis is lacking or modest in most instances; however, occasionally vigorous mixed inflammatory responses are seen. Hypoglycorrhachia and elevated protein levels are found in up to three fourths of cases.

India ink stains will disclose cryptococci in 50% of non-AIDS patients and in as many as 80% of those with AIDS (121). The India ink is positive in 70% to 94% of patients with positive CSF cultures.

Cryptococcal meningitis (positive India ink in CSF)

(Contributed by Dr. Joseph Berger.)

Cryptococcal antigen latex agglutination is a reliable test of the presence of the organism in the CSF as it is positive in more than 90% of patients with meningitis (87; 191; 34; Clark et a 1990; 139; 138) and is a valuable test while awaiting fungal cultures (154). Falsely negative cryptococcal antigen tests may occur. Although in most instances, false negative antigen tests do not appear to be due to a prozone phenomenon or interference from bound antibody or protein (43), occasionally a prozone phenomenon may be observed with spuriously negative studies (102). Like the India ink test, high titer CSF cryptococcal antigen (greater than 2:2034) is seen more commonly in the AIDS patient than the non-AIDS patient with cryptococcal meningitis. Cryptococci are cultured from CSF in virtually all patients with meningitis but less commonly with parenchymal cryptococcomas in the absence of meningitis (191); however, a study of first-episode HIV-associated cryptococcal meningitis in Uganda found that 10% had a sterile culture despite the presence of cryptococcal antigen in the CSF (133). The yield is improved when large volumes of CSF (10 to 30 mL) are removed and cultured. Neither India ink nor CSF cryptococcal antigen studies are reliable measures to assess the adequacy of therapy. CSF fungal cultures are definitive in this regard. Next-generation sequencing has also been demonstrated to be valuable in identifying cryptococcal meningitis (183).

As mentioned, other CSF parameters are frequently abnormal as well. The CSF leukocyte count varies considerably. With rare exception, lymphocytes predominate. White cell counts rarely exceed 800 cells/cu mm (134). Low numbers may occur in the setting of AIDS or corticosteroid administration. The number of cryptococci may exceed the number of leukocytes. A quantitative assessment of the number of viable yeast may yield between 103 and 107 colony-forming units of yeasts per mL of CSF (121). CSF protein levels are high and may exceed 1 g/dL, but are typically in the range of 40 to 600 mg/dL. In those instances where the protein is excessive, a subarachnoid block should be considered. Hypoglycorrhachia may also be seen.

Serologic studies. Cryptococcal antigen titers in serum are usually elevated in patients with cryptococcal meningitis, in some cases even when antigen titers in CSF (34) and CSF cultures for cryptococcal are negative (156). This observation underscores the importance of obtaining serum cryptococcal antigen in all patients suspected of having cryptococcal meningitis. The level of serum cryptococcal antigen and changes in response to therapy do not appear to reliably reflect CSF responses (56; 35; 130). Blood culture may be diagnostic and CSF negative for Cryptococcus in the presence of cryptococcal meningoencephalitis (152). Spuriously negative serum and CSF cryptococcal antigen assay may occur in the presence of high antigen levels (prozone phenomenon), and detection may require dilution (102).

Serum cryptococcal antigen titers may reflect disease disseminated to other organs; this occurs in conjunction with meningitis in up to one half of cases. Titers above 1:8 suggest disseminated cryptococcosis. Most common sites for extrameningeal infection are the lungs, blood, urine, and bone marrow, but virtually any organ may be involved (87; 94; 35; 138).

Management

	• The standard treatment of cryptococcal meningitis in nonpregnant adults is amphotericin B and flucytosine.
	• The duration of induction therapy should be no less than 2 weeks.
	• Following induction therapy, maintenance therapy with fluconazole for 8 weeks is recommended.
	• Routine administration of corticosteroids with the antibiotic regimen is not recommended, though it is helpful in the treatment of IRIS or PIIRS.
	• Increased intracranial pressure may mandate the placement of a shunt.

Authorities have advanced various recommendations regarding the treatment of cryptococcal meningitis in HIV infection. Consensus is that the expectation from treatment is control rather than eradication of infection. Early series reported acute mortalities within six weeks of the completion of therapy of 18% to 37% and, generally, within the first two weeks (87; 34; 35; 139). A variety of treatment regimens were used both within and between studies. A large study from Vietnam of nearly 300 HIV-infected patients with cryptococcal meningitis randomized to amphotericin B alone, amphotericin B and flucytosine, and amphotericin B and fluconazole, convincingly demonstrated that combining high-dose amphotericin B at 1 mg/kg of body weight per day for four weeks with flucytosine 100 mg/kg per day for two weeks resulted in a significantly improved survival (44). There was no survival benefit with the coadministration of fluconazole. The addition of interferon-gamma immunotherapy to standard treatment has been demonstrated to increase clearance of Cryptococcus from the CSF (75).

The standard treatment for cryptococcal meningitis has been amphotericin B at doses of 0.7 to 1.0 kg/day intravenously. Dosages used, however, have ranged from 0.3 to 1.0 mg/kg per day, with higher doses given for shorter periods before reduction to a maintenance regimen (87; 191; 34; 94; 35; 139; 180; 47). The currently recommended doses are either liposomal amphotericin B 3 to 4 mg/kg intravenously per day or amphotericin B lipid complex 5 mg/kg per day (40). Amphotericin B is a polyene antibiotic that binds to ergosterol in the cryptococcal membrane, altering its permeability. Combined induction therapy of amphotericin B combined with flucytosine (02) is generally recommended as this combination has been associated with greater sterilization of the CSF at two weeks and fewer treatment failures (52; 51). The duration of treatment may be as little as two weeks provided that a lumbar puncture documents negative CSF fungal cultures and the intravenous treatment is followed by at least 10 weeks of high dose fluconazole (400 to 800 mg/day orally) as maintenance therapy (02). However, longer treatment durations may be dictated by serious neurologic complications and the response to therapy. In studies prior to AIDS, amphotericin B was found to be more effective in treating cryptococcal meningitis when administered with flucytosine, an oral antimycotic metabolized to 5-fluorouracil within fungal cells, which inhibits fungal DNA and RNA synthesis. Flucytosine may also inhibit purine and pyrimidine uptake by fungi. Myelosuppression from the usual doses of 100 to 150 mg/kg per day has been problematic in AIDS patients, however, limiting its use; gastrointestinal reactions and hepatotoxicity may also occur and cause problems (162; 130). Many large retrospective studies have failed to show survival benefit from combination therapy in AIDS patients, in part due to the impact of toxicity (34; 35). A comparative study of amphotericin B administered intravenously versus a similar group receiving the drug via Ommaya reservoir suggested that CSF cryptococcal clearance and recovery rates were better in the latter group (179). The placement of an Ommaya reservoir may be particularly helpful in the setting of refractory intracranial hypertension (177).

During therapy with amphotericin B, electrolytes and renal function need to be monitored carefully. Renal toxicity, which is related to the cumulative dose administered, is the major limiting adverse effect. During infusion, acute reactions commonly occur with fevers, chills, rigors, headache, and nausea, which may be mitigated by pretreatment with hydrocortisone, nonsteroidal antiinflammatory agents, anti-emetics, and antihistamines. Other potential adverse reactions include seizures, phlebitis, anemia, and edema (162). Amphotericin B is contraindicated in persons who are hypersensitive to the drug or who have significant renal insufficiency. In addition to its nephrotoxicity, other side effects include infusion-related erythema, fever, rigors, hypokalemia, and hypomagnesemia. Patients receiving other nephrotoxic agents should be treated with liposomal amphotericin B.

Attempts to mitigate toxicity from amphotericin B therapy have included incorporation into liposomes (37; 38) and infusion of amphotericin in a fat emulsion (96). Successful responses were obtained in a single patient in the latter instance and a dozen patients in the former. Both regimens were well tolerated. Liposomal amphotericin B is administered as 3 to 6 mg/kg per day intravenously. Doses of amphotericin lipid complex are 5 mg/kg per day. At least three weeks of induction is required when it is used without flucytosine in the setting of renal insufficiency. In general, this expensive preparation is used in the place of amphotericin B only when concomitant nephrotoxic agents are required, there is significant preexisting renal insufficiency (02), or patients have failed other therapies (53).

Flucytosine is administered as 100 mg/kg per day orally in four divided doses and must also be adjusted for renal insufficiency. It is typically administered for two weeks at the inception of therapy. Side effects include bone marrow suppression, azotemia, and hepatic dysfunction. Flucytosine cannot be used as monotherapy due to the rapid development of resistance by the organism.

The development of triazole agents, which inhibit cytochrome P450 enzyme activity by limiting fungal ergosterol synthesis (162), has had a major impact on control of cryptococcal infections in AIDS patients. Fluconazole has a higher CSF penetration than itraconazole, though both have shown efficacy in AIDS patients with cryptococcal meningitis (160; 162; 49; 113). Fluconazole is administered as 400 mg/day in acute therapy and 200 mg/day as suppressive therapy. Side effects include nausea, rash, and hepatitis. Itraconazole is administered as 200 to 400 mg twice daily. Its side effects include nausea, abdominal pain, rash, headache, edema, and hypokalemia. Posaconazole, another triazole antifungal agent, is active against Cryptococcus, but experience with neurologic infection is limited (111).

Comparisons of triazoles with amphotericin B for acute therapy of cryptococcal meningitis in AIDS patients have yielded mixed results to date. The largest trial found no significant difference in overall mortality between fluconazole and amphotericin B, although mortality with fluconazole was concentrated in the first two weeks of illness. Doses of the agents and combination therapy with flucytosine were not controlled (139). Amphotericin B 0.3 mg/kg per day plus flucytosine 150 mg/kg per day was superior to itraconazole 200 mg/day over six weeks in a series (46). Amphotericin B 0.7 mg/kg per day for a week followed by thrice weekly administration for nine weeks in combination with flucytosine 150 mg/day was superior to fluconazole 400 mg/day in another series (95). Variations in dosages, combinations of medications, severity of illness on entry, and definitions of successful outcome among studies limit direct comparisons (130). Fluconazole is administered as 200 to 800 mg/kg per day orally or intravenously. Because of its excellent bioavailability and affordability, the oral preparation is preferred to the parenteral preparation. Alspaugh and Perfect recommend 3 to 9 months of fluconazole maintenance therapy at doses of 200 mg/kg per day in patients without HIV infection and lifelong therapy in the HIV-infected person (02). The drug’s chief side effects are mild nausea and hair loss. A related drug, itraconazole, can be substituted at doses of 200 to 400 mg/kg per day orally or intravenously. Oral itraconazole is an effective prophylactic agent for Cryptococcus in AIDS (26).

Although not an approved therapy in the United States or Europe for cryptococcal infection, an increasing body of experience suggests that voriconazole is an effective antifungal agent (07; 20; 112). Granulocyte/macrophage colony-stimulating factor and interferon are being evaluated as adjunctive therapies. Other potential future therapies include azole antifungals and anticapsular monoclonal antibodies (02). Intrathecal amphotericin B is also an option in treating cryptococcal meningitis refractory to intravenous antifungal treatments (187).

The practice of administering dexamethasone with amphotericin B and fluconazole in HIV-associated cryptococcal meningitis is not supported by data. A double-blind, randomized, placebo-controlled trial comparing HIV-infected patients treated with or without dexamethasone in addition to standard antifungal therapy revealed that it did not reduce mortality and was associated with more adverse events and disability (08). However, in the setting of IRIS or PIIRS in which CNS inflammation is associated with increased intracranial pressure and severe symptoms, corticosteroid use may be warranted. To date, there is no widely recommended dosing regimen. Dexamethasone starting at 20 to 24 mg intravenously daily for one week with subsequent tapering over 4 to 6 weeks or prednisone 60 to 80 mg per day tapered over 4 to 6 weeks have been employed.

Elevated intracranial pressure is common in patients with cryptococcal meningitis and may result in hydrocephalus. It has been postulated that sustained elevations in intracranial pressure may contribute to early mortality by impairing cerebral circulation (49). Therapeutic modalities include drainage by serial lumbar punctures, ventricular drainage, and acetazolamide. The former has been recommended by some authorities when CSF opening pressures equal or exceed 250 mm water (67). Uncontrollable intracranial hypertension may occur in the absence of hydrocephalus, and ventriculoperitoneal shunting may be lifesaving (122). On rare occasion, however, cerebellar tonsillar herniation may occur in the setting of cryptococcal meningitis in the absence of mass lesion (10). Nonetheless, in those individuals with raised intracranial pressure, therapeutic lumbar punctures, particularly in resource poor settings, have been reported to be associated with a 69% relative survival protection (22).

Acute visual loss in patients with HIV-associated cryptococcal meningitis may be transient, abrupt, or progressive and may result from increased intracranial pressure (49), although other causes need to be considered--eg, necrotizing optic neuropathy due to cryptococcal invasion (36) and constrictive arachnoiditis (98). Visual loss in HIV-associated cryptococcal meningitis is independently associated with fungal burden and raised intracranial pressure (109). Patients with papilledema and severely impaired vision may respond to antibiotic therapy alone (66), ventricular shunting of CSF (165), or lysis of arachnoid adhesions (104). The performance of therapeutic lumbar punctures for individuals with high intracranial pressure (> 250 mm H2O) or new symptoms were associated with a significantly reduced mortality (18% vs. 7%), but therapeutic lumbar punctures should be undertaken cautiously (135). Optic nerve sheath fenestration resulted in visual recovery of two patients with cryptococcal meningitis who had persistent associated papilledema and visual loss despite antibiotic therapy (63).

Special considerations

Pregnancy

Both cryptococcal pneumonia (55; 91) and meningitis (124; 151; 41; 79; 158; 85; 32; 33; 120; 28) have been reported during pregnancy. Dissemination of Cryptococcus to the placenta has been reported in the setting of AIDS (85). Whether there is an increased incidence of cryptococcal infection in this population remains unanswered, but a small increment is not unlikely. Although a potential risk of fetal drug toxicity exists, the reported cases to date indicate good survivals of both mother and infant and no lasting toxicity.

Media

References

01: Ahuja J, Soneja M, Wig N, et al. Cryptococcal antigenemia in people living with HIV and AIDS. Int J STD AIDS 2023;34:130-6. PMID 36426734
02: Alspaugh J, Perfect JR. Cryptococcal meningitis. Curr Treat Opt Infect Dis 2002;4(1):75-80.
03: Andreula CF, Burdi N, Carella A. CNS cryptococcosis in AIDS: spectrum of MR findings. J Comput Assist Tomogr 1993;17(3):438-41. PMID 8491907
04: Aquinas SR, Tarey SD, Ravindran GD, Nagamani D, Ross C. Cryptococcal meningitis in AIDS--need for early diagnosis. J Assoc Physicians India 1996;44(3):178-80. PMID 9251313
05: Awasthi M, Patankar T, Shah P, Castillo M. Cerebral cryptococcosis: atypical appearances on CT. Br J Radiol 2001;74(877):83-5. PMID 11227783
06: Baker R, Haugen R. Tissue changes and tissue diagnosis in cryptococcosis, a study of 26 cases. Am J Clin Pathol 1955;25:4-24. PMID 14349908
07: Bandettini R, Castagnola E, Calvillo M, et al. Voriconazole for cryptococcal meningitis in children with leukemia or receiving allogeneic hemopoietic stem cell transplant. J Chemother 2009;21:108-9. PMID 19297284
08: Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med 2016;374(6):542-54. PMID 26863355
09: Benham R. Cryptococcosis and blastomyocosis. Ann NY Acad Sci 1950;50:1299-1314. PMID 14783320
10: Berger JR. The cerebellar seizures of Hughlings Jackson. Neurology 2000;54(1):272. PMID 10908927
11: Berger JR, Moskowitz L, Fischl M, Kelley RE. Neurologic disease as the presenting manifestation of acquired immunodeficiency syndrome. South Med J 1987;80(6):683-6. PMID 3473692
12: Berry AJ, Rinaldi MG, Graybill JR. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother 1992;36(3):690-2. PMID 1622188
13: Bhati R, Pramendra S, Sejoo, et al. Prevalence of asymptomatic cryptococcal antigenemia and association with follow-up risk of cryptococcal meningitis and mortality among HIV infected patients in North West India: A prospective cohort study. Curr HIV Res 2021;19(1):35-39. PMID 32860359
14: Bouffard JP, Mena H, Ripple M, Troncoso J. Mesencephalic cryptococcal abscesses presenting with parkinsonism as an initial manifestation of AIDS. Mov Disord 2003;18(11):1354-7. PMID 14639681
15: Bozzette SA, Larsen RA, Chiu J, et al. A placebo controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Eng J Med 1991;324:580-4. PMID 1992319
16: Broom J, Woods M 2nd, Allworth A. Immune reconstitution inflammatory syndrome producing atypical presentations of cryptococcal meningitis: case report and a review of immune reconstitution-associated cryptococcal infections. Scand J Infect Dis 2006;38(3):219-21. PMID 16500787
17: Buschke A. Ueber eine durch Coccidien Hervergerufene Krankheit des menschen. Deutsche Med Wochenschr 1895;21(3):14.
18: Busse O. Ueber parasitare zelleinschlusse und ihre zuchtung. Zentralbl Bakterial 1894;16:175-80.
19: Campbell LT, Simonin AR, Chen C, et al. Cryptococcus strains with different pathogenic potentials have diverse protein secretomes. Eukaryot Cell 2015;14(6):554-63. PMID 25841021
20: Carbonara S, Regazzi M, Ciraci E, et al. Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis. Ann Pharmacother 2009;43:978-84. PMID 19383934
21: Casadevall A, Spitzer ED, Webb D, Rinaldi MG. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother 1993;37(6):1383-6. PMID 8328793
22: Chang CC, Perfect JR. Repeated therapeutic lumbar punctures in cryptococcal meningitis - necessity and/or opportunity? Curr Opin Infect Dis 2016;29(6):539-45. PMID 27607912
23: Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Datebase Syst Rev 2005;(3):CD004773. PMID 16034947
24: Chang YC, Kwon-Chung KJ. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 1994;14(7):4912-9. PMID 8007987
25: Chang YC, Stins MF, McCaffery MJ, et al. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun 2004;72:4985-95. PMID 15321990
26: Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002;34(2):277-84. PMID 11740718
27: Charlier C, Dromer F, Leveque C, et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS ONE 2008;3:e1950. PMID 18414656
28: Chen CP, Wang KG. Cryptococcal meningitis in pregnancy. Am J Perinatol 1996;13(1):35-6. PMID 8645383
29: Chen SH, Stins MF, Huang SH, et al. Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells. J Med Microbiol 2003;52(Pt 11):961-70. PMID 14532340
30: Cheng S. Factors affecting prognosis of cryptococcal meningitis. Zhonghua Shen Jing Jing Shen Ke Za Zhi 1992;25(4):240-2, 255. PMID 1478145
31: Chong I, Wang KY, Lincoln CM. Cryptococcal meningitis in a multiple sclerosis patient treated with fingolimod: a case report and review of imaging findings. Clin Imaging 2019;54:53-6. PMID 30544079
32: Chotmongkol V, Siricharoensang S. Cryptococcal meningitis in pregnancy: a case report. J Med Assoc Thai 1991;74(9):421-2. PMID 1791397
33: Chotmongkol V, Sookprasert A. Itraconazole in cryptococcal meningitis in pregnancy: a case report. J Med Assoc Thai 1992;75(10):606-8. PMID 1339091
34: Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321(12):794-9.** PMID 2671735
35: Clark RA, Greer D, Atkinson W, Valainis GT, Hyslop N. Spectrum of Cryptococcus neoformans infection in 68 patients infected with human immunodeficiency virus. Rev Infect Dis 1990;12(5):768-77. PMID 2237116
36: Cohen DB, Glasgow BJ. Bilateral optic nerve cryptococcosis in sudden blindness in patients with acquired immune deficiency syndrome. Ophthalmology 1993;100(11):1689-94. PMID 8233396
37: Coker RJ, Murphy SM, Harris JR. Experience with liposomal amphotericin B (AmBisome) in cryptococcal meningitis in AIDS. J Antimicrob Chemother 1991;28(Suppl B):105-9. PMID 1778887
38: Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993;7(6):829-35. PMID 8363759
39: Correa-Forero V, Pinilla-Monsalve GD, Valderrama-Chaparro JA, Amaya-Gonzalez P: Cryptococcal meningitis presenting as acute flaccid paralysis: case report. J Infect Public Health 2020;13(1):143-8. PMID 31350098
40: Cox GM, Perfect JR. Cryptococcus neoformans: treatment of meningoencephalitis and disseminated infection in patients without HIV. UpToDate. Accessed November 2022.
41: Curole DN. Cryptococcal meningitis in pregnancy. J Reprod Med 1981;26(6):317-9. PMID 7252951
42: Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis 1994;19(6):1029-33. PMID 7888529
43: Currie BP, Freundlich LF, Soto MA, Casadevall A. False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis. J Clin Microbiol 1993;31(9):2519-22. PMID 8408579
44: Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013;368(14):1291-302. PMID 23802521
45: de Gans J, Eeftinck Schattenkerk JK, van Ketel RJ. Itraconazole as maintenance treatment for cryptococcal meningitis in the acquired immune deficiency syndrome. Br Med J 1988;296:339. PMID 2830934
46: de Gans J, Portegies P, Tiessens G, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185-90. PMID 1313682
47: de Lalla F, Pellizzer G, Vaglia A, et al. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995;20:263-6. PMID 7742427
48: Delgrange E, Donckier JE. Cryptococcal meningitis and Cushing's syndrome. Lancet 2000;356(9226):343. PMID 11071221
49: Denning DW, Armstrong RW, Lewis BH, Stevens DA. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med 1991;91(3):267-72. PMID 1892147
50: Dismukes W. Cryptococcosis. In: Wyngaarden J, Smith Jr L, Bennett J, editors. Cecil's textbook of medicine. Philadelphia: WB Saunders, 1992:1894-7.
51: Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O; French Cryptococcosis Study Group. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLOS One 2008;3(8):e2870. PMID 18682846
52: Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O; French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the CrypotA/D study. PLoS Med 2007;4:e21. PMID 17284154
53: Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002;49(Suppl A):31-6. PMID 11801578
54: Eisenman HC, Casadevall A, McClelland EE. New insights on the pathogenesis of invasive Cryptococcus neoformans infection. Curr Infect Dis Rep 2007;9(6):457-64. PMID 17999881
55: Ely EW, Peacock JE Jr, Haponik EF, Washburn RG. Cryptococcal pneumonia complicating pregnancy. Medicine (Baltimore) 1998;77(3):153-67. PMID 9653427
56: Eng RH, Bishburg E, Smith SM, Kapila R. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med 1986;81(1):19-23. PMID 3524224
57: Engstrom JW, Lowenstein DH, Bredesen DE. Cerebral infarctions and transient neurologic deficits associated with acquired immunodeficiency syndrome. Am J Med 1989;86(5):528-32. PMID 2712060
58: Fay PM, Strominger MB. Wall-eyed bilateral internuclear ophthalmoplegia in central nervous system cryptococcosis. J Neuroophthalmol 1999;19(2):131-5. PMID 10380136
59: Fraser DW, Ward JI, Ajello L, Plikaytis BD. Aspergillosis and other systemic mycoses. The growing problem. JAMA 1979;242(15):1631-5. PMID 480580
60: Friedman DI. Neuro-ophthalmic manifestations of human immunodeficiency virus infection. Neurol Clin 1991;9(1):55-72. PMID 1849227
61: Fries BC, Lee SC, Kennan R, Zhao W, Casadevall A, Goldman DL. Phenotypic switching of Cryptococcus neoformans can produce variants that elicit increased intracranial pressure in a rat model of cryptococcal meningoencephalitis. Infect Immun 2005;73:1779-87. PMID 15731079
62: Garcia CA, Weisberg LA, Lacorte WS. Cryptococcal intracerebral mass lesions: CT-pathologic considerations. Neurology 1985;35(5):731-4. PMID 3990973
63: Garrity JA, Herman DC, Imes R, Fries P, Hughes CF, Campbell RJ. Optic nerve sheath decompression for visual loss in patients with acquired immunodeficiency syndrome and cryptococcal meningitis with papilledema. Am J Ophthalmol 1993;116(4):472-8. PMID 8213978
64: Giberson TP, Kalyan-Raman K. Cryptococcal meningitis: initial presentation of acquired immunodeficiency syndrome. Ann Emerg Med 1987;16(7):802-4. PMID 3592336
65: Goel D, Kalita J, Misra UK. Basilar artery occlusion in cryptococcal meningitis. Neurol India 1999;47(3):245-6. PMID 10514591
66: Golnik KC, Newman SA, Wispelway B. Cryptococcal optic neuropathy in the acquired immune deficiency syndrome. J Clin Neuroophthalmol 1991;11(2):96-103. PMID 1832692
67: Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000;30(1):47-54. PMID 10619732
68: Gupta S, Ellis M, Cesario T, Ruhling M, Vayuvegula B. Disseminated cryptococcal infection in a patient with hypogammaglobulinemia and normal T cell functions. Am J Med 1987;82(1):129-31. PMID 3492141
69: Hansemann DV. Uber eine bisher nicht beobachtete Gehirnerkrankung durch Hefen. Verh Dtsch Ges Pathol 1905;9:21-4.
70: Hay RJ, Mackenzie DW, Campbell CK, Philpot CM. Cryptococcosis in the United Kingdom and the Irish Republic: an analysis of 69 cases. J Infect 1980;2(1):13-22. PMID 7185913
71: Ho TL, Lee HJ, Lee KW, Chen WL. Diffusion-weighted and conventional magnetic resonance imaging in cerebral cryptococcoma. Acta Radiol 2005;46(4):411-4. PMID 16134319
72: Jabs DA, Green WR, Fox R, Polk BF, Bartlett JG. Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology 1989;96(7):1092-9.** PMID 2549483
73: Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis 2014;58(5):736-45. PMID 24319084
74: Jarvis JN, Meintjes G, Bicanic T, et al. Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. PLoS Pathog 2015;11(4):e1004754. PMID 25853653
75: Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012;26(9):1105-13. PMID 22421244
76: Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002;35(12):e128-33. PMID 12471589
77: Jimenez-Lucho V, Ginsburg V, Krivan HC. Cryptococcus neoformans, Candida albicans, and other fungi bind specifically to the glycosphingolipid lactosylceramide (Gal beta 1-4Glc beta 1-1Cer), a possible adhesion receptor for yeasts. Infect Immun 1990;58(7):2085-90. PMID 2194958
78: Johannessen DJ, Wilson LG. Mania with cryptococcal meningitis in two AIDS patients. J Clin Psychiatry 1988;49(5):200-1. PMID 3366757
79: Jones JM, Craig WA. Cryptococcal meningitis: resolution eight months after antifungal therapy. South Med J 1983;76(12):1567-9. PMID 6648619
80: Kalita J, Bansal R, Ayagiri A, Misra UK. Midbrain infarction: a rare presentation of cryptococcal meningitis. Clin Neurol Neurosurg 1999;101(1):23-5. PMID 10350199
81: Kalra SP, Chadha DS, Singh AP, Sanchetee PC, Mohapatra AK. Cryptococcal meningitis in acquired immunodeficiency syndrome. J Assoc Physicians India 1999;47(10):958-61. PMID 10778686
82: Kanaly CW, Selznick LA, Cummings TJ, Adamson DC. Cerebellar cryptococcoma in a patient with undiagnosed sarcoidosis: case report. Neurosurgery 2007;60:E571. PMID 17327765
83: Keane JR. Neuro-ophthalmologic signs of AIDS: 50 patients. Neurology 1991;41(6):841-5. PMID 2046928
84: Keane JR. Intermittent third nerve palsy with cryptococcal meningitis. J Clin Neuroophthalmol 1993;13(2):124-6. PMID 8340478
85: Kida M, Abramowsky CR, Santoscoy C. Cryptococcosis of the placenta in a woman with acquired immunodeficiency syndrome. Hum Pathol 1989;20(9):920-1. PMID 2777245
86: Koshy JM, Mohan S, Deodhar D, John M, Oberoi A, Pannu A. Clinical Diversity of CNS Cryptococcosis. J Assoc Physicians India 2017;65(10):15-9. PMID 29319242
87: Kovacs JA, Kovacs AA, Polis M, et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103(4):533-8. PMID 3898951
88: Kuruvilla A. Cryptococcal meningitis and Cushing's syndrome. Lancet 2000;356(9226):342-3. PMID 11071220
89: Kwon-Chung KJ, Fraser JA, Doering TL, et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med 2014;4(7):a019760. PMID 24985132
90: Kwon-Chung KJ, Rhodes JC. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun 1986;51(1):218-23.** PMID 3079732
91: LaGatta MA, Jordan C, Khan W, Toomey J. Isolated pulmonary cryptococcosis in pregnancy. Obstet Gynecol 1998;92(4 Pt 2):682-4. PMID 9764663
92: Lan SH, Chang WN, Lu CH, Lui CC, Chang HW. Cerebral infarction in chronic meningitis: a comparison of tuberculous meningitis and cryptococcal meningitis. QIM 2001;94(5):247-53. PMID 11353098
93: Lang W, Miklossy J, Deruaz JP, et al. Definition and incidence of AIDS-associated CNS lesions. Prog AIDS Pathol 1990;2:89-101. PMID 1966526
94: Larsen RA, Bozzette S, McCutchan JA, Chiu J, Leal MA, Richman DD. Persistent cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. Ann Intern Med 1989;111:125-8. PMID 2545124
95: Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990;113:183-7. PMID 2197908
96: Leake HA, Appleyard MN, Hartley JP. Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B. J Infect 1994;28(3):319-22. PMID 8089520
97: Lee YC, Wang JT, Sun HY, Chen YC. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J Microbiol Immunol Infect 2011;44(5):338-45. PMID 21524972
98: Lipson BK, Freeman WR, Beniz J, et al. Optic neuropathy associated with cryptococcal arachnoiditis in AIDS patients. Am J Ophthalmol 1989;107(5):523-7. PMID 2540660
99: Liu J, Wei H, Liu J, et al. Analysis of the association of HLA subtypes with cryptococcal meningitis in HIV-negative immunocompetent patients. Future Microbiol 2022;17:1231-40. PMID 35984285
100: Lu CH, Chang WN, Chang HW, Chuang YC. The prognostic factors of cryptococcal meningitis in HIV-negative patients. J Hosp Infect 1999;42(4):313-20. PMID 10467545
101: Lui G, Lee N, Ip M, et al. Cryptococcosis in apparently immunocompetent patients. QJM 2006;99:143-51. PMID 16504989
102: Malik AAA, Periyasamy P, Kori N, Wahab AA, Ding CH. A spuriously negative cryptococcal antigen assay result in disseminated cryptococcosis: the deception of the postzone phenomenon. Ann Clin Lab Sci 2021;51(3):430-3. PMID 34162576
103: Manfredi R, Mazzoni A, Nanetti A, Mastroianni A, Coronado O, Chiodo F. Morphologic features and clinical significance of skin involvement in patients with AIDS-related cryptococcosis. Acta Derm Venereol 1996;76(1):72-4. PMID 8721500
104: Maruki C, Nakano H, Shimoji T, Maeda M, Ishii S. Loss of vision due to cryptococcal optochiasmatic arachnoiditis and optocurative surgical exploration--case report. Neurol Med Chir (Tokyo) 1988;28(7):695-7. PMID 2462180
105: Mathews VP, Alo PL, Glass JD, Kumar AJ, McArthur JC. AIDS-related CNS cryptococcosis: radiologic-pathologic correlation. AJNR Am J Neuroradiol 1992;13:1477-86. PMID 1414845
106: Merkel GJ, Scofield BA. Conditions affecting the adherence of Cryptococcus neoformans to rat glial and lung cells in vitro. J Med Vet Mycol 1993;31(1):55-64. PMID 8483058
107: Minamoto GY, Rosenberg AS. Fungal infections in patients with acquired immunodeficiency syndrome. Med Clin North Am 1997;81(2):381-409. PMID 9093234
108: Mishra AK, Arvind VH, Muliyil D, et al. Cerebrovascular injury in cryptococcal meningitis. Int J Stroke 2018;13(1):57-65. PMID 28421878
109: Molloy SF, Ross B, Kanyama C, et al. Fungal burden and raised intracranial pressure are independently associated with visual loss in human immunodeficiency-associated cryptococcal meningitis. Open Forum Infect Dis 2021;8(4):ofab066. PMID 33937434
110: Murai H, Tokunaga H, Kubo I, et al. Myeloradiculitis caused by Cryptococcus neoformans infection in a patient with ulcerative colitis: a neuropathological study. J Neurol Sci 2006;247:236-8. PMID 16815466
111: Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45(12):1610-7. PMID 18190324
112: Nierenberg NE, Thompson GR, Lewis JS, Hogan BK, Patterson TF. Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. Med Mycol 2010;48(3):532-6. PMID 19835489
113: Nightingale SD, Cal SX, Peterson DM, et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992;6:191-4. PMID 1348417
114: Nsenga L, Kajjimu J, Olum R, et al. Cryptococcosis complicating diabetes mellitus: a scoping review. Ther Adv Infect Dis 2021;5;8:20499361211014769. PMID 33996076
115: Nunnari G, Gussio M, Pinzone MR, et al. Cryptococcal meningitis in an HIV-1-infected person: relapses or IRIS. Case report and review of the literature. Eur Rev Med Pharmacol Sci 2013;17(11):1555-9. PMID 23771547
116: Ofner S, Baker RS. Visual loss in cryptococcal meningitis. J Clin Neuroophthalmol 1987;7(1):45-8. PMID 2952681
117: Okun E, Butler W. Ophthalmologic complications of cryptococcal meningitis. Arch Ophthalmol 1964;71:52-7. PMID 14066039
118: Paugam A, Dupouy-Camet J, Blanche P, Gangneux JP, Tourte-Schaefer C, Sicard D. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis 1994;19(5):975-6. PMID 7893896
119: Peetermans W, Bobbaers H, Verhaegen J, Vandepitte J. Fluconazole-resistant Cryptococcus neoformans var gattii in an AIDS patient. Acta Clin Belg 1993;48(6):405-9. PMID 8128821
120: Pereira CA, Fischman O, Colombo AL, Moron AF, Pignatari AC. Cryptococcal meningitis in pregnancy. Review of the literature. Report of 2 cases. Rev Inst Med Trop Sao Paulo 1993;35(4):367-71. PMID 8115798
121: Perfect JR, Durack DT, Gallis HA. Cryptococcemia. Medicine (Baltimore) 1983;62(2):98-109.** PMID 6338344
122: Petrou P, Moscovici S, Leker RR, Itshayek E, Gomori JM, Cohen JE. Ventriculoperitoneal shunt for intracranial hypertension in cryptococcal meningitis without hydrocephalus. J Clin Neurosci 2012;19(8):1175-6. PMID 22658489
123: Pham C, Bennett I, Jithoo R. Cryptococcal meningitis causing obstructive hydrocephalus in a patient on fingolimod. BMJ Case Rep 2017;2017. PMID 28687690
124: Philpot CR, Lo D. Cryptococcal meningitis in pregnancy. Med J Aust 1972;2(18):1005-7. PMID 4578877
125: Pinner RW, Hajjeh RA, Powderly WG. Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21(Suppl 1):S103-7. PMID 8547496
126: Pool A, Lowder L, Wu Y, Forrester K, Rumbaugh J. Neurovirulence of Cryptococcus neoformans determined by time course of capsule accumulation and total volume of capsule in the brain. J Neurovirol 2013;19(3):228-38. PMID 23733307
127: Popovich MJ, Arthur RH, Helmer E. CT of intracranial cryptococcosis. AJNR Am J Neuroradiol 1990;11(1):139-42. PMID 2105596
128: Porter KG, Sinnamon DG, Gillies RR. Cryptococcus neoformans-specific oligoclonal immunoglobulins in cerebrospinal fluid in cryptococcal meningitis. Lancet 1977;1(8024):1262. PMID 68362
129: Post MJ, Kursunoglu SJ, Hensley GT, Chan JC, Moskowitz LB, Hoffman TA. Cranial CT in acquired immunodeficiency syndrome: spectrum of diseases and optimal contrast enhancement technique. AJR Am J Roentgenol 1985;145(5):929-40. PMID 3876751
130: Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992;326(12):793-8. PMID 1538722
131: Pyrgos V, Seitz AE, Steiner CA, Prevots DR, Williamson PR. Epidemiology of cryptococcal meningitis in the US: 1997-2009. PLoS One 2013;8(2):e56269. PMID 23457543
132: Reynard P, Bascuol A, Biotti D, Karsenty J, Ionescu E, Thai-Van H. Audiovestibular neuropathy in an immunocompetent man with cryptococcal meningitis. Eur Ann Otorhinolaryngol Head Neck Dis 2020;S1879-7296(20):30251-9. PMID 33092984
133: Rhein J, Huppler Hullsiek K, Tugume L, et al. Adjunctive sertraline in HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infect Dis 2019;19(8):843-51. PMID 31345462
134: Rippon J. Cryptococcosis. Medical mycology: The pathogenic fungi and the pathogenic actinomycetes. Philadelphia: WB Saunders, 1988:582-609.
135: Rolfes MA, Hullsiek KH, Rhein J, et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis 2014;59(11):1607-14. PMID 25057102
136: Rosario M, Song SX, McCullough LD. An unusual case of stroke. Neurologist 2012;18:229-32. PMID 22735255
137: Ross JJ, Katz JD. Cryptococcal meningitis and sarcoidosis. Scand J Infect Dis 2002;34(12):937-9. PMID 12587633
138: Rozenbaum R, Goncalves AJ. Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis 1994;18(3):369-80.** PMID 8011818
139: Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992;326(2):83-9. PMID 1727236
140: Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001;56(2):257-60. PMID 11160967
141: Sadun F, De Negri AM, Santopadre P, Pivetti Pezzi P. Bilateral trochlear nerve palsy associated with cryptococcal meningitis in human immunodeficiency virus infection. J Neuroopthalmol 1999;19(2):118-9. PMID 10380131
142: Saigal G, Post MJ, Lolayekar S, Murtaza A. Unusual presentation of central nervous system cryptococcal infection in an immunocompetent patient. AJNR Am J Neuroradiol 2005;26:2522-6. PMID 16286394
143: Sancesario G, Palmieri G, Viola G, et al. Difficulty diagnosing chronic cryptococcal meningitis in idiopathic CD4+ lymphocytopenia. Neurol Sci 2011;32:19-24. PMID 21384279
144: Saul RF, Gallagher JG, Mateer JE. Sudden hemiparesis as the presenting sign in cryptococcal meningoencephalitis. Stroke 1986;17(4):753-4. PMID 3738961
145: Schimpff SC, Bennett JE. Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J Allergy Clin Immunol 1975;55(6):430-41. PMID 1094054
146: Seaton RA, Naraqi S, Wembri JP, Warrell DA. Predictors of outcome in Cryptococcus neoformans var. gattii meningitis. QJM 1996;89(6):423-8. PMID 8758045
147: Selby RC, Lopes NM. Torulomas (cryptococcal granulomata) of the central nervous system. J Neurosurg 1973;38(1):40-6. PMID 4565922
148: Shen CC, Cheng WY, Yang MY. Isolated intramedullary cryptococcal granuloma of the conus medullaris: case report and review of the literature. Scend J Infect Dis 2006;38:562-5. PMID 16798715
149: Shi ZW, Chen Y, Ogoke KM, Strickland AB, Shi M. Cryptococcal immune reconstitution inflammatory syndrome: from clinical studies to animal experiments. Microorganisms 2022;10(12)2419. PMID 36557672
150: Shih CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Cryptococcal meningitis in non-HIV-infected patients. QJM 2000;93(4):245-51.** PMID 10787453
151: Silberfarb PM, Sarosi GA, Tosh FE. Cryptococcosis and pregnancy. Am J Obstet Gynecol 1972;112(5):714-20. PMID 4551034
152: Sivasangeetha K, Harish BN, Sujatha S, Parija SC, Dutta TK. Cryptococcal meningoencephalitis diagnosed by blood culture. Indian J Med Microbiol 2007;25(3):282-4. PMID 17901653
153: Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect 2005;51:e289-97. PMID 16321643
154: Snow RM, Dismukes E. Cryptococcal meningitis: diagnostic value of cryptococcal antigen in cerebrospinal fluid. Arch Intern Med 1975;135(9):1155-7. PMID 1100006
155: Spitzer ED, Spitzer SG, Freundlich LF, Casadevall A. Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet 1993;341:595-6. PMID 8094831
156: Ssebambulidde K, Bangdiwala AS, Kwizera R, et al. Symptomatic cryptococcal antigenemia presenting as early cryptococcal meningitis with negative cerebral spinal fluid analysis. Clin Infect Dis 2019;20;68(12):2094-98. PMID 30256903
157: Stack M, Hiles J, Valeinetz E, Gupta SK, Butt S, Schneider JG. Cryptococcal meningitis in young, immunocopetent patients: a single-center retrospective case series and review of the literature. Open Forum Infect Dis 2023;10(8):ofad420. PMID 37636518
158: Stafford CR, Fisher JF, Fadel HE, Espinel-Ingroff AV, Shadomy S, Hamby M. Cryptococcal meningitis in pregnancy. Obstet Gynecol 1983;62(3 Suppl):35s-7s. PMID 6877708
159: Steenbergen JN, Shuman HA, Casadevall A. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A 2001;98(26):15245-50. PMID 11742090
160: Stern JJ, Hartman BJ, Sharkey P, et al. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med 1988;85(4):477-80. PMID 2845778
161: Stoddard J, Cutler E. Torula infection in man. Rockfeller Inst Med Res Monograph 1916;62:1-98.
162: Sugar AM, Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med 1988;85(4):481-9. PMID 2845779
163: Sungkanuparph S, Filler SG, Chetchotisakd P, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis 2009;49(6):931-4. PMID 19681708
164: Taelman H, Clerinx J, Kagame A, Batungwanayo J, Nyirabareja A, Bogaerts J. Cryptococcosis, another growing burden for central Africa. Lancet 1991;338(8769):761. PMID 1679896
165: Tan C. Intracranial hypertension causing visual failure in cryptococcus meningitis. Psychiatry 1988;51:944-6. PMID 3204403
166: Tantisiriwat W, Powderly W. Cryptococcus. In: Schlossberg D, editor. Current therapy of infectious disease. St. Louis: Mosby, 2001:708-12.
167: Tien RD, Chu PK, Hesselink JR, Duberg A, Wiley C. Intracranial cryptococcosis in immunocompromised patients: CT and MR findings in 29 cases. AJNR Am J Neuroradiol 1991;12(2):283-9. PMID 1902029
168: Tornero Estebanez C, Paricio Blasco A, Pons Espana E. A cerebral infarct associated with cryptococcal meningitis in an AIDS patient. An Med Interna 1992;9(4):206-7. PMID 1581461
169: Touma M, Rasmussen LD, Martin-Iguacel R, et al. Incidence, clinical presentation, and outcome of HIV-1-associated cryptococcal meningitis during the highly active antiretroviral therapy era: a nationwide cohort study. Clin Epidemiol 2017;9:385-92. PMID 28790866
170: Tsai ST, Lin FY, Chen PS, Chiang HY, Kuo CC. Three year mortality in cryptococcal meningitis: Hyperglycemia predict unfavorable outcome. PLoS One 2021;16(5):e0251749. PMID 34048463
171: Ulett KB, Cockburn JW, Jeffree R, Woods ML. Cerebral cryptococcoma mimicking glioblastoma. BMJ Case Rep 2017;2017. PMID 28188169
172: Valenzuela RM, Pula JH, Garwacki D, Cotter J, Kattah JC. Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab. J Neurol Sci 2014;340(1-2):109-11. PMID 24680560
173: Vibhagool A, Sungkanuparph S Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003;36(10):1329-31. PMID 12746781
174: Vinters H, Anders K. Neuropathology of AIDS. Boca Raton: CRC Press, 1990.
175: Vuillemin P. Le Blastomycetes pathogenes. Rev Gen Sci 1901;12:32-51.
176: Wake RM, Molloy SF, Jarvis JN, Harrison TS, Govender NP. Cryptococcal antigenemia in advanced human immunodeficiency viruse disease: pathophysiology, epidemiology, and clinical implications. Clin Infect Dis 2023;76(4):764-70. PMID 35986670
177: Wan Y, Li X, Wang Y, Yu Y, Yang S. Clinical characteristic of 15 cases of cryptococcal meningitis treated with Ommaya reservoir. Acta Neurol Belg 2020;120(5):1139-45. PMID 31321616
178: Wang W, Carm AR. Clinical manifestations of AIDS with cryptococcal meningitis. Chin Med J (Engl) 2001;114(8):841-3. PMID 11780363
179: Wei B, Qian C, Liu Y, Lin X, Wan J, Wang Y. Ommaya reservoir in the treatment of cryptococcal meningitis. Acta Neurol Belg 2017;117(1):283-7. PMID 27492153
180: White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992;165(5):960-3. PMID 1569350
181: Wilbur L, Heyborne R. Transient loss of consciousness caused by cryptococcal meningitis in an immunocompetent patient: a case report. Cases J 2009:2:60. PMID 19146689
182: Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S. Cryptococcal meningitis, an analysis among 5,521 consecutive organ transplant recipients. Transpl Infect Dis 2002;4(4):183-8. PMID 12535260
183: Xing XW, Zhang JT, Ma YB, Zheng N, Yang F, Yu SY. Apparent performance of metagenomic next-generation sequencing in the diagnosis of cryptococcal meningitis: a descriptive study. J Med Microbiol 2019;68(8):1204-10. PMID 31184572
184: York J, Bodi I, Reeves I, Riordan-Eva P, Easterbrook PJ. Raised intracranial pressure complicating cryptococcal meningitis: immune reconstitution inflammatory syndrome or recurrent cryptococcal disease. J Infect Dis 2005;51(2):165-71. PMID 15961162
185: Yu YL, Lau YN, Woo E, Wong KL, Tse B. Cryptococcal infection of the nervous system. Q J Med 1988;66(249):87-96.** PMID 3174924
186: Yu YL, Woo E, Chan FL, Chan TY, Chan GC. Cerebral infarction in cryptococcal meningitis. Clin Exp Neurol 1989;26:193-7. PMID 2642128
187: Yuchong C, Jianghan C, Hai W, Julin G. Lumbar puncture drainage with intrathecal injection of amphotericin B for control of cryptococcal meningitis. Mycoses 2011;54(4):e248-51. PMID 20070534
188: Zhang L, Liu T, Kong W, et al. Decreased TLR2 signal expression in peripheral blood mononuclear cell from patients with cryptococcal meningitis. Microbiol Immunol 2015;59(6):357-64. PMID 25951991
189: Zhou Q, Gault RA, Kozel TR, Murphy WJ. Protection from direct cerebral Cryptococcus infection by interferon-gamma-dependent activation of microglial cells. J Immunol 2007;178(9):5753-61. PMID 17442959
190: Zhou QH, Hu CQ, Shi Y, et al. Cryptococcosis in patients with liver cirrhosis: death risk factors and predictive value of prognostic models. Hepatobiliary Pancreat Dis Int 2021;20(5):460-8. PMID 34233849
191: Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med 1986;104(2):234-40. PMID 3946951

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Joseph R Berger MD

Dr. Berger of the Perelman School of Medicine, University of Pennsylvania, received consultant honorariums from Celegene/BMS, Cellevolve, EMD Serono/Merck, Genentech, Genzyme, Janssen/J&J, Morphic, Novartis, Roche, Sanofi, Takeda, and TG Therapeutics. He received honorariums from MAPI and ExcisionBio as a scientific advisory or data safety monitoring board member. And he received research support from Biogen and Genentech/Roche.
See Profile

Editor

John E Greenlee MD

Dr. Greenlee of the University of Utah School of Medicine has no relevant financial relationships to disclose.
See Profile

Former Authors

Sidney Houff MD PhD (original author)

Patient Profile

Age range of presentation: 0 month 65+ years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Cryptococcosis: 117.5

Cryptococcal meningitis: 321.0
ICD-10: Cryptococcosis: B45.9

Cryptococcal meningitis: G02.1

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Cryptococcal meningitis

Differential Diagnosis

headache
encephalopathy
stroke
seizure
glioma
- certain viral meningitides
- some forms of bacterial meningitis
- tuberculous meningitis
- partially treated bacterial meningitis
- other fungal meningitides
- parasitic meningitis
- amebic meningitis
- trichinosis
- carcinomatous meningitis
- lymphomatous meningitis
- drug-induced meningitis
- chemical meningitis
- meningitis accompanying connective tissue diseases
- systemic lupus erythematosus
- rheumatoid arthritis

Also Relevant

Headache associated with HIV and AIDS
HIV-associated dementia
AIDS and HIV: neurologic manifestations and complications
Molecular diagnosis of CNS infections
Recurrent meningitis
- Transplantation: neurologic complications

Cryptococcal meningitis …

Cryptococcal meningitis

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

Questions or Comment?

Also in This Category

Prion diseases

Rabies

Malaria

Neuropathies associated with cytomegalovirus infection

Genital herpes: neurologic complications

Neurocysticercosis

Trichinosis

Metal neurotoxicity